title: [Health care and infective aspects in patients affected by common variable immunodeficiency assisted in the Lazio Regional Authority Reference Centre for Primary Immunodeficiencies].
abstract: Common variable immunodeficiency (CVID) is a chronic condition characterised by a predominant defect of humoral immunity. In most cases the diagnosis of CVID is made during adulthood; the main clinical features of CVID are chronic and relapsing infections (mainly of respiratory and gastroenteric tracts). CVID patients may also develop neoplastic and autoimmune diseases. In our centre (the Regional Centre for Primary Immunodeficiencies of the Lazio Regional Authority) we administered a 23-item questionnaire to 60 patients with CVID undergoing substitutive therapy with intravenous immunoglobulins (IVIG) about their demographic characteristics, time of clinical onset, time of diagnosis of CVID, clinical features, IVIG doses and administration intervals, and self-assessment of health status. In addition, the clinical history of all patients was reviewed, and the levels of serum IgG, IgA and IgM were evaluated and compared with the pre-therapy serum concentration. Moreover, an analysis of the treatment costs was performed. At onset, 67.2% of patients presented recurrent respiratory infections, and 50% had infections of the lower respiratory tract; 39.6% of the patients had gastroenteric infections. Most patients (57%) had recurrent infections of at least 2 of the respiratory, gastroenteric and/or urogenital tracts. In 37.9% of the group the diagnosis of CVID was made in less than 2 years after the beginning of symptoms, but in many cases (22.4%) the diagnosis took more than 10 years. 93% of patients are treated with a dose of IVIG between 6 and 15 g per administration, with intervals between 2 and 3 weeks. The review of patients'clinical history showed that 43% of patients have had respiratory infections during the follow-up in our Centre, 43% have splenomegaly (3% were also subjected to splenectomy) and 18.3% have autoimmune diseases. The mean concentration of IgG before the beginning of IVIG therapy was 235 mg/dl, while during the follow-up it was 664 mg/dl. Given the long time often required for diagnosis, general physicians and specialists should be better informed in order to make diagnosis swifter. The substitutive therapy with IVIG is effective in preventing recurrent infections and complications. A thorough follow-up is important for diagnosing neoplastic and autoimmune complications; in addition, immunologic analysis of peripheral blood and bone marrow are useful in identifying subgroups of patients with more severe clinical features. Finally, in selected patients, treatment costs may be controlled by modifying the dosage of IVIG or the intervals between administrations.
authors.affiliation: Dottorato di Ricerca in Scienze Infettivologiche e delle Terapie Immunologiche, Università degli Studi di Roma, La Sapienza, Roma, Italy.
authors.forename: W
authors.initials: W
authors.lastname: De Santis
authors.forename: A
authors.initials: A
authors.lastname: Esposito
authors.forename: V
authors.initials: V
authors.lastname: Conti
authors.forename: A
authors.initials: A
authors.lastname: Fantauzzi
authors.forename: A
authors.initials: A
authors.lastname: Guerra
authors.forename: I
authors.initials: I
authors.lastname: Mezzaroma
authors.forename: F
authors.initials: F
authors.lastname: Aiuti
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001327:Autoimmune Diseases / Q000453:epidemiology / Q000209:etiology; D002648:Child; D002675:Child, Preschool; D017074:Common Variable Immunodeficiency / Q000150:complications / Q000175:diagnosis / Q000191:economics / Q000453:epidemiology* / Q000628:therapy; D003141:Communicable Diseases / Q000191:economics / Q000453:epidemiology* / Q000209:etiology; D003953:Diagnosis-Related Groups; D004198:Disease Susceptibility; D005260:Female; D005500:Follow-Up Studies; D017048:Health Care Costs; D006782:Hospitals, Special / Q000706:statistics & numerical data; D006801:Humans; D016867:Immunocompromised Host; D016756:Immunoglobulins, Intravenous / Q000191:economics / Q000627:therapeutic use; D007223:Infant; D007558:Italy / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000453:epidemiology / Q000209:etiology; D012017:Referral and Consultation / Q000706:statistics & numerical data; D012384:Rome / Q000453:epidemiology; D011795:Surveys and Questionnaires
chemical_list: D016756:Immunoglobulins, Intravenous